Recently, Hickey and co-workers [43] re-evaluated the role of the AR in breast cancer and provided compelling evidence for the use of an agonist to activate AR signalling as a therapeutic intervention in ER+ breast cancers. This evidence concerns the gene AR and breast cancer.